Compare FET & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | ZVRA |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 850.2M | 689.4M |
| IPO Year | 2007 | 2015 |
| Metric | FET | ZVRA |
|---|---|---|
| Price | $82.30 | $10.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 135.0K | ★ 746.1K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 92.64 | ★ 159.21 |
| EPS | 0.39 | ★ 0.74 |
| Revenue | ★ $791,474,000.00 | $106,470,000.00 |
| Revenue This Year | $12.04 | $42.97 |
| Revenue Next Year | $5.92 | $16.27 |
| P/E Ratio | $206.21 | ★ $15.19 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $25.25 | $8.01 |
| 52 Week High | $87.42 | $15.04 |
| Indicator | FET | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 35.04 |
| Support Level | $77.71 | $10.18 |
| Resistance Level | $84.18 | $11.07 |
| Average True Range (ATR) | 2.75 | 0.38 |
| MACD | -0.59 | -0.11 |
| Stochastic Oscillator | 33.91 | 0.32 |
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.